NZ555334A - Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist - Google Patents

Info

Publication number

NZ555334A

NZ555334A NZ555334A NZ55533405A NZ555334A NZ 555334 A NZ555334 A NZ 555334A NZ 555334 A NZ555334 A NZ 555334A NZ 55533405 A NZ55533405 A NZ 55533405A NZ 555334 A NZ555334 A NZ 555334A

Authority

NZ

New Zealand

Prior art keywords

substituted

alkyl

phenyl

benzyl

aryl

Prior art date

2004-12-24

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 title claims abstract description 85
• 230000002981 neuropathic effect Effects 0.000 title claims description 47
• 238000011282 treatment Methods 0.000 title claims description 17
• 238000011321 prophylaxis Methods 0.000 title claims description 10
• 238000000034 method Methods 0.000 title description 52
• 150000001875 compounds Chemical class 0.000 claims abstract description 130
• 208000004296 neuralgia Diseases 0.000 claims abstract description 46
• 150000003839 salts Chemical class 0.000 claims abstract description 46
• 208000021722 neuropathic pain Diseases 0.000 claims abstract description 45
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 168
• -1 phenyloxy, benzyl Chemical group 0.000 claims description 144
• 125000001424 substituent group Chemical group 0.000 claims description 107
• 125000003118 aryl group Chemical group 0.000 claims description 102
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 92
• 125000001072 heteroaryl group Chemical group 0.000 claims description 82
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 81
• 101150116411 AGTR2 gene Proteins 0.000 claims description 74
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 66
• 229910052739 hydrogen Inorganic materials 0.000 claims description 59
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
• 229910052760 oxygen Inorganic materials 0.000 claims description 58
• 125000005843 halogen group Chemical group 0.000 claims description 55
• 239000001257 hydrogen Substances 0.000 claims description 55
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 54
• 229920001184 polypeptide Polymers 0.000 claims description 51
• 229910052717 sulfur Inorganic materials 0.000 claims description 51
• 239000004305 biphenyl Substances 0.000 claims description 48
• 239000001301 oxygen Substances 0.000 claims description 48
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 47
• 229910052757 nitrogen Inorganic materials 0.000 claims description 44
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 41
• 239000011593 sulfur Substances 0.000 claims description 41
• 125000000623 heterocyclic group Chemical group 0.000 claims description 40
• 125000003545 alkoxy group Chemical group 0.000 claims description 39
• 235000010290 biphenyl Nutrition 0.000 claims description 36
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 36
• 239000000203 mixture Substances 0.000 claims description 32
• 229910052794 bromium Inorganic materials 0.000 claims description 30
• 229910052740 iodine Inorganic materials 0.000 claims description 30
• 201000001119 neuropathy Diseases 0.000 claims description 25
• 230000007823 neuropathy Effects 0.000 claims description 25
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 25
• 230000027455 binding Effects 0.000 claims description 24
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
• 150000002431 hydrogen Chemical group 0.000 claims description 22
• 229920006395 saturated elastomer Polymers 0.000 claims description 22
• 230000014509 gene expression Effects 0.000 claims description 20
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 17
• 125000003107 substituted aryl group Chemical group 0.000 claims description 17
• 125000003282 alkyl amino group Chemical group 0.000 claims description 16
• 229910052799 carbon Inorganic materials 0.000 claims description 16
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 15
• 230000005714 functional activity Effects 0.000 claims description 15
• 150000002367 halogens Chemical class 0.000 claims description 15
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
• 102000039446 nucleic acids Human genes 0.000 claims description 13
• 108020004707 nucleic acids Proteins 0.000 claims description 13
• 150000007523 nucleic acids Chemical class 0.000 claims description 13
• 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 13
• 108090000994 Catalytic RNA Proteins 0.000 claims description 12
• 102000053642 Catalytic RNA Human genes 0.000 claims description 12
• 239000000427 antigen Substances 0.000 claims description 12
• 108091007433 antigens Proteins 0.000 claims description 12
• 102000036639 antigens Human genes 0.000 claims description 12
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 12
• 238000002347 injection Methods 0.000 claims description 12
• 239000007924 injection Substances 0.000 claims description 12
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
• 108091092562 ribozyme Proteins 0.000 claims description 12
• 239000003085 diluting agent Substances 0.000 claims description 11
• 230000009368 gene silencing by RNA Effects 0.000 claims description 11
• 125000001624 naphthyl group Chemical group 0.000 claims description 11
• 125000002837 carbocyclic group Chemical group 0.000 claims description 10
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
• 208000028389 Nerve injury Diseases 0.000 claims description 9
• 230000008764 nerve damage Effects 0.000 claims description 9
• CCGOFLIRJQWGAA-UHFFFAOYSA-N N-benzyl-2-phenyl-6-phenylmethoxyaniline Chemical group C(C1=CC=CC=C1)OC=1C(=C(C=CC=1)C1=CC=CC=C1)NCC1=CC=CC=C1 CCGOFLIRJQWGAA-UHFFFAOYSA-N 0.000 claims description 8
• 229910019142 PO4 Inorganic materials 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
• 150000001408 amides Chemical class 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 230000002093 peripheral effect Effects 0.000 claims description 7
• 239000010452 phosphate Substances 0.000 claims description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
• 230000000699 topical effect Effects 0.000 claims description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
• 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 6
• 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 6
• 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 6
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
• 230000000692 anti-sense effect Effects 0.000 claims description 6
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 6
• 150000007942 carboxylates Chemical class 0.000 claims description 6
• 125000004986 diarylamino group Chemical group 0.000 claims description 6
• 229950003188 isovaleryl diethylamide Drugs 0.000 claims description 6
• 125000005541 phosphonamide group Chemical group 0.000 claims description 6
• 229940124530 sulfonamide Drugs 0.000 claims description 6
• 150000003456 sulfonamides Chemical class 0.000 claims description 6
• 101150099866 AT2 gene Proteins 0.000 claims description 5
• 125000001769 aryl amino group Chemical group 0.000 claims description 5
• 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 4
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
• 125000001153 fluoro group Chemical group F* 0.000 claims description 4
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
• 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 3
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
• ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 3
• 229930182819 D-leucine Natural products 0.000 claims description 3
• 239000004471 Glycine Substances 0.000 claims description 3
• QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
• 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 claims description 3
• 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
• 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 3
• 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
• 229910018828 PO3H2 Inorganic materials 0.000 claims description 3
• 239000002253 acid Substances 0.000 claims description 3
• 229960003767 alanine Drugs 0.000 claims description 3
• 125000004104 aryloxy group Chemical group 0.000 claims description 3
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
• 125000005241 heteroarylamino group Chemical group 0.000 claims description 3
• 229960000310 isoleucine Drugs 0.000 claims description 3
• 150000002825 nitriles Chemical class 0.000 claims description 3
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
• 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 2
• 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 2
• 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 2
• 125000005240 diheteroarylamino group Chemical group 0.000 claims description 2
• 239000000816 peptidomimetic Substances 0.000 claims description 2
• 150000003384 small molecules Chemical group 0.000 claims description 2
• GHBCIXGRCZIPNQ-MHZLTWQESA-N (3s)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@H](N(CC1=CC=C2OC)C(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)C(O)=O)C1=C2OCC1=CC=CC=C1 GHBCIXGRCZIPNQ-MHZLTWQESA-N 0.000 claims 2
• 125000002114 valyl group Chemical group 0.000 claims 2
• GHBCIXGRCZIPNQ-UHFFFAOYSA-N 2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical group COC1=CC=C2CN(C(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)C(C(O)=O)CC2=C1OCC1=CC=CC=C1 GHBCIXGRCZIPNQ-UHFFFAOYSA-N 0.000 claims 1
• MIKCHUZDARMSDF-UHFFFAOYSA-N 7h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C1C(C(=O)O)=NC=C2N=CN=C21 MIKCHUZDARMSDF-UHFFFAOYSA-N 0.000 claims 1
• 229930182844 L-isoleucine Natural products 0.000 claims 1
• 108091030071 RNAI Proteins 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 description 187
• 208000004454 Hyperalgesia Diseases 0.000 description 92
• 241000700159 Rattus Species 0.000 description 62
• 206010012601 diabetes mellitus Diseases 0.000 description 55
• 208000002193 Pain Diseases 0.000 description 53
• 238000012360 testing method Methods 0.000 description 50
• 238000007912 intraperitoneal administration Methods 0.000 description 48
• 125000000753 cycloalkyl group Chemical group 0.000 description 47
• 210000000548 hind-foot Anatomy 0.000 description 44
• 230000036407 pain Effects 0.000 description 42
• 239000003795 chemical substances by application Substances 0.000 description 40
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 36
• 210000004027 cell Anatomy 0.000 description 34
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 32
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 32
• 108090000623 proteins and genes Proteins 0.000 description 31
• 208000024891 symptom Diseases 0.000 description 31
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 28
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 28
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 26
• 125000003342 alkenyl group Chemical group 0.000 description 25
• 231100000673 dose–response relationship Toxicity 0.000 description 24
• 206010053552 allodynia Diseases 0.000 description 23
• 230000003447 ipsilateral effect Effects 0.000 description 22
• 239000003446 ligand Substances 0.000 description 22
• 230000004044 response Effects 0.000 description 22
• 230000009471 action Effects 0.000 description 21
• 241001465754 Metazoa Species 0.000 description 20
• 102000040430 polynucleotide Human genes 0.000 description 20
• 108091033319 polynucleotide Proteins 0.000 description 20
• 239000002157 polynucleotide Substances 0.000 description 20
• 125000004429 atom Chemical group 0.000 description 19
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 19
• 239000013598 vector Substances 0.000 description 19
• 125000004414 alkyl thio group Chemical group 0.000 description 17
• 150000001413 amino acids Chemical group 0.000 description 17
• 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 17
• 230000003502 anti-nociceptive effect Effects 0.000 description 16
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 15
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 14
• 125000004122 cyclic group Chemical group 0.000 description 14
• 208000014674 injury Diseases 0.000 description 14
• KDPHUUTUDFDLBT-UHFFFAOYSA-N n-benzyl-n-[2-ethyl-4-oxo-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]thiophene-2-carboxamide Chemical compound CCC1=NC2=CC=C(N(CC=3C=CC=CC=3)C(=O)C=3SC=CC=3)C=C2C(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KDPHUUTUDFDLBT-UHFFFAOYSA-N 0.000 description 14
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 13
• 230000003574 anti-allodynic effect Effects 0.000 description 13
• 125000004432 carbon atom Chemical group C* 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 125000005842 heteroatom Chemical group 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 12
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 12
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 12
• 125000000732 arylene group Chemical group 0.000 description 12
• 230000001684 chronic effect Effects 0.000 description 12
• 125000004093 cyano group Chemical group *C#N 0.000 description 12
• 230000006378 damage Effects 0.000 description 12
• 230000002265 prevention Effects 0.000 description 12
• 239000002464 receptor antagonist Substances 0.000 description 12
• 229940044551 receptor antagonist Drugs 0.000 description 12
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 11
• 229940024606 amino acid Drugs 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000018109 developmental process Effects 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 125000004193 piperazinyl group Chemical group 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• 210000003497 sciatic nerve Anatomy 0.000 description 11
• 229960001052 streptozocin Drugs 0.000 description 11
• 239000003981 vehicle Substances 0.000 description 11
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
• 208000027418 Wounds and injury Diseases 0.000 description 10
• 125000004450 alkenylene group Chemical group 0.000 description 10
• 125000002947 alkylene group Chemical group 0.000 description 10
• 125000004419 alkynylene group Chemical group 0.000 description 10
• 210000002683 foot Anatomy 0.000 description 10
• 239000012634 fragment Substances 0.000 description 10
• 230000006698 induction Effects 0.000 description 10
• CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 10
• 159000000000 sodium salts Chemical class 0.000 description 10
• 238000001356 surgical procedure Methods 0.000 description 10
• 101800000733 Angiotensin-2 Proteins 0.000 description 9
• 102400000345 Angiotensin-2 Human genes 0.000 description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
• 229950006323 angiotensin ii Drugs 0.000 description 9
• 201000010099 disease Diseases 0.000 description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
• 125000002757 morpholinyl group Chemical group 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 9
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
• 108091034117 Oligonucleotide Proteins 0.000 description 8
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• 125000000304 alkynyl group Chemical group 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 229940090044 injection Drugs 0.000 description 8
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
• 125000002950 monocyclic group Chemical group 0.000 description 8
• 210000005036 nerve Anatomy 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• 230000036592 analgesia Effects 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 229910052731 fluorine Inorganic materials 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
• 150000003254 radicals Chemical class 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 6
• 208000035154 Hyperesthesia Diseases 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 241000006334 Phyllosma Species 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 6
• 125000002252 acyl group Chemical group 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 239000001913 cellulose Substances 0.000 description 6
• 229920002678 cellulose Polymers 0.000 description 6
• 235000010980 cellulose Nutrition 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• XVSYDLITVYBCBD-UHFFFAOYSA-N cyclopent-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CC=CC1 XVSYDLITVYBCBD-UHFFFAOYSA-N 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 238000011552 rat model Methods 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 5
• 108020005544 Antisense RNA Proteins 0.000 description 5
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
• 125000001118 alkylidene group Chemical group 0.000 description 5
• 239000003184 complementary RNA Substances 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 125000002541 furyl group Chemical group 0.000 description 5
• 125000005549 heteroarylene group Chemical group 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 5
• 210000004731 jugular vein Anatomy 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
• 235000021317 phosphate Nutrition 0.000 description 5
• 125000002098 pyridazinyl group Chemical group 0.000 description 5
• 238000012453 sprague-dawley rat model Methods 0.000 description 5
• 125000001544 thienyl group Chemical group 0.000 description 5
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 4
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
• 108020004491 Antisense DNA Proteins 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 239000001828 Gelatine Substances 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• 108700008625 Reporter Genes Proteins 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 101710101155 Type-2 angiotensin II receptor Proteins 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 108010023606 Zinc Finger E-box-Binding Homeobox 1 Proteins 0.000 description 4
• 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000008485 antagonism Effects 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 239000003816 antisense DNA Substances 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 238000009396 hybridization Methods 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 125000001041 indolyl group Chemical group 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 229960002725 isoflurane Drugs 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 125000002971 oxazolyl group Chemical group 0.000 description 4
• 230000037324 pain perception Effects 0.000 description 4
• 230000008058 pain sensation Effects 0.000 description 4
• 235000019371 penicillin G benzathine Nutrition 0.000 description 4
• 229940056360 penicillin g Drugs 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 229920000573 polyethylene Polymers 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 125000003373 pyrazinyl group Chemical group 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 125000000168 pyrrolyl group Chemical group 0.000 description 4
• 230000011514 reflex Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
• 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 3
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 3
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 208000007514 Herpes zoster Diseases 0.000 description 3
• 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 208000001294 Nociceptive Pain Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 101000890948 Rattus norvegicus Type-2 angiotensin II receptor Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
• SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 125000003968 arylidene group Chemical group [H]C(c)=* 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
• 125000001246 bromo group Chemical group Br* 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 239000008298 dragée Substances 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000000763 evoking effect Effects 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
• 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 125000002883 imidazolyl group Chemical group 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000001473 noxious effect Effects 0.000 description 3
• 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 125000000714 pyrimidinyl group Chemical group 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• 125000001425 triazolyl group Chemical group 0.000 description 3
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
• AZKOXDMCRLYWTD-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[7-[2-(2h-tetrazol-5-yl)phenyl]-3,4-dihydro-2h-chromen-4-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C1=CC=2)CCOC1=CC=2C1=CC=CC=C1C1=NN=NN1 AZKOXDMCRLYWTD-UHFFFAOYSA-N 0.000 description 2
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
• 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 239000002083 C09CA01 - Losartan Substances 0.000 description 2
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
• GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
• 208000001387 Causalgia Diseases 0.000 description 2
• 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 2
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 101100295741 Gallus gallus COR4 gene Proteins 0.000 description 2
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 229910004727 OSO3H Inorganic materials 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 208000005298 acute pain Diseases 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000006347 bis(trifluoromethyl)hydroxymethyl group Chemical group [H]OC(*)(C(F)(F)F)C(F)(F)F 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 210000004900 c-terminal fragment Anatomy 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 229960000932 candesartan Drugs 0.000 description 2
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000007877 drug screening Methods 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000002616 endonucleolytic effect Effects 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 125000001183 hydrocarbyl group Chemical group 0.000 description 2
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
• 229960004773 losartan Drugs 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 description 2
• 125000003835 nucleoside group Chemical group 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 125000004043 oxo group Chemical group O=* 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000003884 phenylalkyl group Chemical group 0.000 description 2
• 150000008298 phosphoramidates Chemical class 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 125000002577 pseudohalo group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000008736 traumatic injury Effects 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 230000036642 wellbeing Effects 0.000 description 2
• 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
• YGIIVECFPDENQX-UHFFFAOYSA-N 1-[5-[(2-cyclopropyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]pyridin-2-yl]cyclopentane-1-carboxylic acid Chemical compound C=1C=C(C2(CCCC2)C(O)=O)N=CC=1CN1C2=NC(C)=CC(C)=C2N=C1C1CC1 YGIIVECFPDENQX-UHFFFAOYSA-N 0.000 description 1
• HQUADHGHLGHLPS-UHFFFAOYSA-N 1-[5-[(2-cyclopropyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]thiophen-2-yl]cyclopenta-2,3-diene-1-carboxylic acid Chemical compound C=1C=C(C2(C=C=CC2)C(O)=O)SC=1CN1C2=NC(C)=CC(C)=C2N=C1C1CC1 HQUADHGHLGHLPS-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• IPIORGCOGQZEHO-UHFFFAOYSA-N 1-propan-2-ylimidazole Chemical compound CC(C)N1C=CN=C1 IPIORGCOGQZEHO-UHFFFAOYSA-N 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
• AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
• XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 1
• ZUYKJZQOPXDNOK-UHFFFAOYSA-N 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CSC=1C1(NCC)CCCCC1=O ZUYKJZQOPXDNOK-UHFFFAOYSA-N 0.000 description 1
• NUDUQRFWVVQTNT-UHFFFAOYSA-N 2-(trifluoromethyl)pyrazole-3-carboxylic acid Chemical compound OC(=O)C1=CC=NN1C(F)(F)F NUDUQRFWVVQTNT-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• ZEHOZMDFRMYTCP-UHFFFAOYSA-N 2-[5-(2-butylimidazo[4,5-b]pyridin-3-yl)naphthalen-2-yl]benzoic acid Chemical compound CCCCC1=NC2=CC=CN=C2N1C(C1=CC=2)=CC=CC1=CC=2C1=CC=CC=C1C(O)=O ZEHOZMDFRMYTCP-UHFFFAOYSA-N 0.000 description 1
• VNQPSUICAKULSP-UHFFFAOYSA-N 2-[5-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]thiophen-2-yl]-1,3-dihydroindene-2-carboxylic acid Chemical compound C1C2=CC=CC=C2CC1(C(O)=O)C(S1)=CC=C1CN1C2=NC(C)=CC(C)=C2N=C1CC VNQPSUICAKULSP-UHFFFAOYSA-N 0.000 description 1
• CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical class CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• IMKSXAAOJOLBAS-UHFFFAOYSA-N 2-butyl-3-[6-[2-(2h-tetrazol-5-yl)phenyl]naphthalen-1-yl]imidazo[4,5-b]pyridine Chemical compound CCCCC1=NC2=CC=CN=C2N1C(C1=CC=2)=CC=CC1=CC=2C1=CC=CC=C1C1=NN=NN1 IMKSXAAOJOLBAS-UHFFFAOYSA-N 0.000 description 1
• RAQQIOZQVDYPKU-UHFFFAOYSA-N 2-butyl-3-[[5-(1-carboxycyclopent-3-en-1-yl)thiophen-2-yl]methyl]-5-chloroimidazole-4-carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C2(CC=CC2)C(O)=O)S1 RAQQIOZQVDYPKU-UHFFFAOYSA-N 0.000 description 1
• YSZHMALINCPBEN-UHFFFAOYSA-N 2-butyl-5-(1,1,2,2,2-pentafluoroethyl)-3-[5-[2-(2h-tetrazol-5-yl)phenyl]-2,3-dihydro-1h-inden-1-yl]imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(C(F)(F)C(F)(F)F)=C(C(O)=O)N1C1C2=CC=C(C=3C(=CC=CC=3)C3=NNN=N3)C=C2CC1 YSZHMALINCPBEN-UHFFFAOYSA-N 0.000 description 1
• FCWDRARIMBHNAD-UHFFFAOYSA-N 2-butyl-5-chloro-3-[5-[2-(2h-tetrazol-5-yl)phenyl]-2,3-dihydro-1h-inden-1-yl]imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1C1C2=CC=C(C=3C(=CC=CC=3)C3=NNN=N3)C=C2CC1 FCWDRARIMBHNAD-UHFFFAOYSA-N 0.000 description 1
• VTOCJNAOUJGQCB-UHFFFAOYSA-N 2-butyl-5-ethyl-3-[5-[2-(2h-tetrazol-5-yl)phenyl]-2,3-dihydro-1h-inden-1-yl]imidazole-4-carboxylic acid Chemical compound CCCCC1=NC(CC)=C(C(O)=O)N1C1C2=CC=C(C=3C(=CC=CC=3)C3=NNN=N3)C=C2CC1 VTOCJNAOUJGQCB-UHFFFAOYSA-N 0.000 description 1
• KVHCBGFGXVLDGD-UHFFFAOYSA-N 2-cyclopropyl-5,7-dimethyl-3-[5-[2-(2h-tetrazol-5-yl)phenyl]-2,3-dihydro-1h-inden-1-yl]imidazo[4,5-b]pyridine Chemical compound C1CC2=CC(C=3C(=CC=CC=3)C=3NN=NN=3)=CC=C2C1N1C2=NC(C)=CC(C)=C2N=C1C1CC1 KVHCBGFGXVLDGD-UHFFFAOYSA-N 0.000 description 1
• PNPLZUQIELLKKG-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[2-[2-(2h-tetrazol-5-yl)phenyl]-5,6-dihydro-4h-cyclopenta[b]thiophen-4-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=1C=2)CCC=1SC=2C1=CC=CC=C1C=1N=NNN=1 PNPLZUQIELLKKG-UHFFFAOYSA-N 0.000 description 1
• BHIGKXHDHYLTLJ-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[2-[2-(2h-tetrazol-5-yl)phenyl]-5,6-dihydro-4h-thieno[2,3-b]thiopyran-4-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=1C=2)CCSC=1SC=2C1=CC=CC=C1C=1N=NNN=1 BHIGKXHDHYLTLJ-UHFFFAOYSA-N 0.000 description 1
• GIPGFQCNSQHSAF-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[5-[3-(2h-tetrazol-5-yl)thiophen-2-yl]-2,3-dihydro-1h-inden-1-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C1=CC=2)CCC1=CC=2C=1SC=CC=1C=1N=NNN=1 GIPGFQCNSQHSAF-UHFFFAOYSA-N 0.000 description 1
• SCKAPBHSUIUXPK-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[5-[4-(2h-tetrazol-5-yl)pyridin-3-yl]-2,3-dihydro-1h-inden-1-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C1=CC=2)CCC1=CC=2C1=CN=CC=C1C=1N=NNN=1 SCKAPBHSUIUXPK-UHFFFAOYSA-N 0.000 description 1
• WRBDQAHGRZCOFZ-UHFFFAOYSA-N 2-ethyl-5,7-dimethyl-3-[5-[4-(2h-tetrazol-5-yl)thiophen-3-yl]-2,3-dihydro-1h-inden-1-yl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C1=CC=2)CCC1=CC=2C1=CSC=C1C=1N=NNN=1 WRBDQAHGRZCOFZ-UHFFFAOYSA-N 0.000 description 1
• APOPELUUNSACIT-UHFFFAOYSA-N 2-ethylsulfanyl-3-[5-[2-(2h-tetrazol-5-yl)phenyl]-2,3-dihydro-1h-inden-1-yl]benzimidazole-4-carboxylic acid Chemical compound CCSC1=NC2=CC=CC(C(O)=O)=C2N1C(C1=CC=2)CCC1=CC=2C1=CC=CC=C1C=1N=NNN=1 APOPELUUNSACIT-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 101150055869 25 gene Proteins 0.000 description 1
• WXNIXCUFZXPXJK-UHFFFAOYSA-N 3-[[5-(1-carboxycyclopent-3-en-1-yl)thiophen-2-yl]methyl]-5-ethyl-2-propylimidazole-4-carboxylic acid Chemical compound CCCC1=NC(CC)=C(C(O)=O)N1CC1=CC=C(C2(CC=CC2)C(O)=O)S1 WXNIXCUFZXPXJK-UHFFFAOYSA-N 0.000 description 1
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
• ZXBYHDZDJAYUGT-UHFFFAOYSA-N 4-[5-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]thiophen-2-yl]oxane-4-carboxylic acid Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1CC(S1)=CC=C1C1(C(O)=O)CCOCC1 ZXBYHDZDJAYUGT-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
• NZACNJVAZXTIPC-UHFFFAOYSA-N 5,7-dimethyl-1h-imidazo[4,5-b]pyridine Chemical compound CC1=CC(C)=C2N=CNC2=N1 NZACNJVAZXTIPC-UHFFFAOYSA-N 0.000 description 1
• RQLOLOLPOYNOBW-UHFFFAOYSA-N 5-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)-2-[2-(2h-tetrazol-5-yl)phenyl]-5,6,7,8-tetrahydroquinoline Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C1=CC=2)CCCC1=NC=2C1=CC=CC=C1C=1N=NNN=1 RQLOLOLPOYNOBW-UHFFFAOYSA-N 0.000 description 1
• JIODROHVBDVOTQ-UHFFFAOYSA-N 5-butyl-4-[[5-(1-carboxycyclopent-3-en-1-yl)thiophen-2-yl]methyl]-2-propylpyrazole-3-carboxylic acid Chemical compound CCCCC1=NN(CCC)C(C(O)=O)=C1CC1=CC=C(C2(CC=CC2)C(O)=O)S1 JIODROHVBDVOTQ-UHFFFAOYSA-N 0.000 description 1
• MIVICWZPMVWWSP-UHFFFAOYSA-N 6-amino-1h-quinazolin-2-one Chemical class N1C(=O)N=CC2=CC(N)=CC=C21 MIVICWZPMVWWSP-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 239000004925 Acrylic resin Substances 0.000 description 1
• 229920000178 Acrylic resin Polymers 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• 229910014585 C2-Ce Inorganic materials 0.000 description 1
• 108010026667 CGP 42112A Proteins 0.000 description 1
• UXGNARZDONUMMK-LRMQDCNJSA-N CGP-42112A Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)C=1C=NC=CC=1)CC1=CN=CN1 UXGNARZDONUMMK-LRMQDCNJSA-N 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• 241000282421 Canidae Species 0.000 description 1
• 241000824799 Canis lupus dingo Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000025962 Crush injury Diseases 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
• QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
• 206010065952 Hyperpathia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• WZNWNDJUFWUPTP-UHFFFAOYSA-N N-[3-(4-ethyl-2-propylimidazol-1-yl)-3-oxopropyl]-N-pyridin-3-ylbutanamide Chemical compound CCCC(=O)N(CCC(=O)N1C=C(CC)N=C1CCC)C1=CC=CN=C1 WZNWNDJUFWUPTP-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 235000019482 Palm oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 101100490685 Rattus norvegicus Agtr2 gene Proteins 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 229910006069 SO3H Inorganic materials 0.000 description 1
• 108010083387 Saralasin Proteins 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical class OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 239000004164 Wax ester Substances 0.000 description 1
• GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 125000005275 alkylenearyl group Chemical group 0.000 description 1
• 125000005025 alkynylaryl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000001949 anaesthesia Methods 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 230000000798 anti-retroviral effect Effects 0.000 description 1
• 239000006067 antibiotic powder Substances 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 229910052785 arsenic Inorganic materials 0.000 description 1
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940085274 benzocaine 5 mg Drugs 0.000 description 1
• 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 229960003150 bupivacaine Drugs 0.000 description 1
• 229940013767 bupivacaine injection Drugs 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• JUDBPCYNUQJHIU-UHFFFAOYSA-N butyl n-[2-[4-[[4-ethyl-2-propyl-5-[3-[pyridine-3-carbonyl(pyridin-3-yl)amino]propanoyl]imidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=CC=C1C(C=C1F)=CC=C1CN1C(C(=O)CCN(C(=O)C=2C=NC=CC=2)C=2C=NC=CC=2)=C(CC)N=C1CCC JUDBPCYNUQJHIU-UHFFFAOYSA-N 0.000 description 1
• ZUUBORJFIVFRAP-UHFFFAOYSA-N butyl n-[2-[4-[[4-ethyl-5-[2-(2-phenoxyphenoxy)acetyl]-2-propylimidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=CC=C1C(C=C1F)=CC=C1CN1C(C(=O)COC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C(CC)N=C1CCC ZUUBORJFIVFRAP-UHFFFAOYSA-N 0.000 description 1
• OMFYNUIXBSRGMP-UHFFFAOYSA-N butyl n-[2-[4-[[4-ethyl-5-[3-(2-phenoxyphenyl)propanoyl]-2-propylimidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=CC=C1C(C=C1F)=CC=C1CN1C(C(=O)CCC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C(CC)N=C1CCC OMFYNUIXBSRGMP-UHFFFAOYSA-N 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000004623 carbolinyl group Chemical group 0.000 description 1
• OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical group [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
• 125000004956 cyclohexylene group Chemical group 0.000 description 1
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229960002656 didanosine Drugs 0.000 description 1
• UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
• UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
• 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 1
• WIULKAASLBZREV-RXPQEOCGSA-N dihydrocytochalasin b Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)CCC(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 WIULKAASLBZREV-RXPQEOCGSA-N 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
• 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
• 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
• 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
• 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• KLWYPRNPRNPORS-UHFFFAOYSA-N ethyl 1h-imidazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CN1 KLWYPRNPRNPORS-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 150000002344 gold compounds Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 125000005553 heteroaryloxy group Chemical group 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
• 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 101150029559 hph gene Proteins 0.000 description 1
• 102000057366 human AGTR2 Human genes 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
• 229940097277 hygromycin b Drugs 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 150000004701 malic acid derivatives Chemical class 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
• 229950000752 methylhexaneamine Drugs 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• UGUIIQBEKPBTNM-UHFFFAOYSA-N n-benzyl-n-[2-ethyl-4-oxo-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]thiophene-2-carboxamide;sodium Chemical compound [Na].CCC1=NC2=CC=C(N(CC=3C=CC=CC=3)C(=O)C=3SC=CC=3)C=C2C(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 UGUIIQBEKPBTNM-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
• 230000003533 narcotic effect Effects 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
• 229940053050 neomycin sulfate Drugs 0.000 description 1
• 210000001640 nerve ending Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960001907 nitrofurazone Drugs 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 235000018343 nutrient deficiency Nutrition 0.000 description 1
• 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000008533 pain sensitivity Effects 0.000 description 1
• 239000002540 palm oil Substances 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• PRQCYNPROFSHME-UHFFFAOYSA-N propyl n-[2-[4-[[5-[3-(n-benzoylanilino)propanoyl]-4-ethyl-2-propylimidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate Chemical compound CCCOC(=O)NS(=O)(=O)C1=CC=CC=C1C(C=C1F)=CC=C1CN1C(C(=O)CCN(C(=O)C=2C=CC=CC=2)C=2C=CC=CC=2)=C(CC)N=C1CCC PRQCYNPROFSHME-UHFFFAOYSA-N 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 1
• 229960004785 saralasin Drugs 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• CRDYSYOERSZTHZ-UHFFFAOYSA-M selenocyanate Chemical compound [Se-]C#N CRDYSYOERSZTHZ-UHFFFAOYSA-M 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000020341 sensory perception of pain Effects 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 150000003900 succinic acid esters Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
• 229960000551 sulfacetamide sodium Drugs 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 150000003899 tartaric acid esters Chemical class 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 125000005425 toluyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 235000019386 wax ester Nutrition 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 229960004175 xylazine hydrochloride Drugs 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• 229960001366 zolazepam Drugs 0.000 description 1